Retatrutide: The Triple Agonist GLP-1 Research Guide (2026)

Retatrutide is the GLP-1 compound researchers and weight loss clinicians have been watching most closely since tirzepatide's approval. Phase 2 trial data published in the New England Journal of Medicine showed 24.2% average body weight reduction at 48 weeks -- a figure that outpaced everything that came before it. This guide covers how retatrutide works, what the trial data actually shows, how it compares to semaglutide and tirzepatide, and what researchers sourcing it for laboratory purposes should know.

What Is Retatrutide?

The benefit side of the trial data is in Retatrutide benefits.

Retatrutide (also designated LY3437943) is a once-weekly injectable peptide developed by Eli Lilly. It is a triple agonist: it activates three distinct receptors simultaneously.

• GLP-1 receptor (glucagon-like peptide-1): reduces appetite, slows gastric emptying, increases insulin secretion in response to food
• GIP receptor (glucose-dependent insulinotropic polypeptide): amplifies insulin response, improves insulin sensitivity, modulates fat storage
• Glucagon receptor: increases energy expenditure, accelerates fat oxidation, acts on the liver to reduce hepatic fat

The first two receptors (GLP-1 and GIP) are also targeted by tirzepatide (Mounjaro/Zepbound). The glucagon component is what sets retatrutide apart. Glucagon receptor activation raises basal metabolic rate and directly mobilizes fat stores, which is why the weight loss numbers from Phase 2 data were notably higher than dual-agonist compounds.

Phase 2 Clinical Trial Results

The key retatrutide trial enrolled 338 adults with obesity or overweight. Participants received weekly injections at one of four dose levels or placebo for 48 weeks. Results published in NEJM in 2023 and updated with extended follow-up data since:

At the 12mg dose, 26% of participants lost more than 30% of their body weight. The weight loss curve at 48 weeks had not yet flattened, suggesting results would have continued improving with longer treatment.

How the Triple Agonist Mechanism Works

Each receptor layer adds a distinct effect. Understanding which does what helps explain the data.

GLP-1 Component

GLP-1 activation reduces appetite through central satiety signaling and delays gastric emptying. This is the same mechanism as semaglutide. Most of the nausea and GI side effects associated with GLP-1 drugs come from this pathway.

GIP Component

GIP amplifies the insulin response to meals and appears to reduce GLP-1-related nausea when co-activated. There is evidence the GIP component in tirzepatide is partly responsible for it having better tolerability than semaglutide at equivalent weight loss levels. Retatrutide carries this benefit as well.

Glucagon Component

The glucagon pathway is where retatrutide diverges from tirzepatide. Glucagon receptor activation:

• Raises basal metabolic rate (thermogenesis)
• Increases fatty acid oxidation in the liver
• Reduces hepatic fat accumulation (relevant for NAFLD/MASH research)
• May preserve lean mass during weight loss compared to GLP-1 alone

The tradeoff is that glucagon activation alone raises blood glucose. The simultaneous GLP-1 and GIP activation counteracts this, keeping glucose levels stable. The three-way balance is what makes the formulation work without causing hyperglycemia.

Retatrutide vs Tirzepatide vs Semaglutide

The practical implication: each generation has produced meaningfully better efficacy than the last. Retatrutide's Phase 3 toplines answered that question in 2026: 28.3% at 80 weeks on 12 mg in TRIUMPH-1 (2,339 adults), against 24.2% at 48 weeks in Phase 2. The peer-reviewed papers, with the more conservative treatment-regimen figures, are still to come.

Side Effect Profile

The most common adverse events in Phase 2 trials were GI-related, consistent with all GLP-1 class compounds:

• Nausea: 42-58% across active dose groups (mild to moderate in most cases)
• Vomiting: 16-26% across active dose groups
• Diarrhea: 18-28%
• Constipation: 10-18%
• Decreased appetite: expected and consistent

GI events were highest in the first 4-8 weeks during titration and decreased over time for most participants. Trial discontinuation due to adverse events was 16% at 12mg, which is higher than tirzepatide but in line with semaglutide at high doses.

Heart rate increase (similar to other GLP-1 compounds) was observed. No serious hypoglycemia events were reported in participants without diabetes.

Research Dosing Protocols from Trial Data

For reference purposes, the Phase 2 trial used the following titration schedules (not a clinical recommendation):

4mg Cohort

1. Weeks 1-4: 0.5mg weekly
2. Weeks 5-8: 1mg weekly
3. Weeks 9-12: 2mg weekly
4. Week 13+: 4mg weekly (maintenance)

8mg Cohort

1. Weeks 1-4: 0.5mg weekly
2. Weeks 5-8: 1mg weekly
3. Weeks 9-12: 2mg weekly
4. Weeks 13-16: 4mg weekly
5. Week 17+: 8mg weekly (maintenance)

12mg Cohort

1. Weeks 1-4: 0.5mg weekly
2. Weeks 5-8: 1mg weekly
3. Weeks 9-12: 2mg weekly
4. Weeks 13-16: 4mg weekly
5. Weeks 17-20: 8mg weekly
6. Week 21+: 12mg weekly (maintenance)

All dosing used subcutaneous injection once weekly. The slow titration schedule is specifically designed to minimize GI adverse events during the adjustment period.

Current Research Applications

Beyond obesity, retatrutide is being investigated for:

• MASH (metabolic dysfunction-associated steatohepatitis): the glucagon component's effect on hepatic fat makes it particularly relevant for liver disease research
• Type 2 diabetes: the triple receptor activation offers a different glycemic control profile than existing GLP-1 agents
• Cardiovascular and kidney outcomes: TRIUMPH-Outcomes (NCT06383390), a roughly five-year trial in adults with a BMI of 27 or higher and atherosclerotic cardiovascular disease or chronic kidney disease, is running alongside the weight-loss trials
• Lean mass preservation: early research suggests the glucagon component may produce more favorable fat-to-muscle loss ratio compared to GLP-1-only agents

What Separates Quality Research Vendors

GLP-1 peptides are more complex to synthesize and verify than simpler peptides like BPC-157 or ipamorelin. A few things to look for when sourcing retatrutide for research:

• Third-party HPLC and mass spec: the COA should come from an independent lab, not just the manufacturer. HPLC purity should be 98%+ for research-grade material.
• Sequence confirmation: mass spectrometry confirms the correct peptide sequence. Without this, you can have high purity of the wrong molecule.
• Endotoxin testing: relevant for any injectable research application. Bacterial endotoxins can produce confounding inflammatory responses in lab work.
• Lyophilized format: retatrutide should be shipped as a lyophilized powder, not pre-reconstituted. Stability in solution is limited compared to dry form.
• Cold chain handling: even lyophilized, proper shipping and storage conditions matter. Vendors should use cold packs and insulated packaging.

For anything GLP-1-class, the COA is the most important document. Read it, verify the issuing lab is real, and confirm the test date is recent (within 6-12 months).

Reconstitution and Storage

Retatrutide reconstitution follows standard peptide protocols:

• Reconstitute with bacteriostatic water (not sterile water) for multi-use vials
• Add solvent slowly down the side of the vial -- do not inject directly onto the powder
• Swirl gently, never vortex or shake vigorously
• Reconstituted solution: store at 2-8C (refrigerator), use within 28 days
• Lyophilized powder: store at -20C for long-term, 2-8C for short-term (up to 3 months)
• Protect from light throughout storage

See the full reconstitution guide for complete protocol and equipment list.

Phase 3 Timeline and What to Watch

Eli Lilly's Phase 3 TRIUMPH programme has now reported topline results from four trials. All four are company press releases rather than peer-reviewed papers, and all quote the efficacy estimand, which counts participants who stayed on treatment, so the published treatment-regimen figures will be somewhat lower.

• TRIUMPH-4 (445 adults with obesity or overweight and knee osteoarthritis, 68 weeks), reported 11 December 2025: mean weight loss of 26.4% on 9 mg and 28.7% on 12 mg, against 2.1% on placebo.
• TRIUMPH-1 (2,339 adults with obesity or overweight, 80 weeks), reported 21 May 2026: 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, against 2.2% on placebo. 45.3% of the 12 mg group lost 30% or more of their body weight. A pre-specified 104-week extension in 532 participants with a baseline BMI of 35 or higher reached 30.3% on 12 mg.
• TRIUMPH-2 (1,152 adults with type 2 diabetes and obesity or overweight, 80 weeks), reported 23 July 2026: 12.7% on 4 mg, 19.1% on 9 mg and 20.8% on 12 mg, against 4.0% on placebo, with an A1C reduction of up to 1.6% at the highest dose.
• TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease, 80 weeks), reported the same day: 21.6% on 9 mg and 22.6% on 12 mg, against 3.2% on placebo.

Lilly has said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. From a filing at that point, late 2027 is the earliest realistic decision under a priority review and 2028 is more likely under a standard one, which is why the dosage guide keeps 2027 or 2028 as the approval window.

What is still open: the peer-reviewed publications with complete adverse-event tables, the remaining registrational trials in the programme (obstructive sleep apnea among them), and TRIUMPH-Outcomes (NCT06383390), the roughly five-year cardiovascular and kidney outcomes trial that will decide whether the cardiovascular benefit seen with semaglutide in SELECT extends to the triple agonist class. The before-and-after page carries the week-by-week curve from every TRIUMPH arm.